News

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against The 2024 Highly Pathogenic H5N1 Avian Influenza Strain
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain <li /> The Company's virolo ...